Krystal Biotech Statistics
Total Valuation
Krystal Biotech has a market cap or net worth of $8.98 billion. The enterprise value is $7.80 billion.
| Market Cap | 8.98B |
| Enterprise Value | 7.80B |
Important Dates
The last earnings date was Monday, November 2, 2026, before market open.
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Krystal Biotech has 29.63 million shares outstanding. The number of shares has increased by 2.44% in one year.
| Current Share Class | 29.63M |
| Shares Outstanding | 29.63M |
| Shares Change (YoY) | +2.44% |
| Shares Change (QoQ) | +0.59% |
| Owned by Insiders (%) | 9.93% |
| Owned by Institutions (%) | 89.94% |
| Float | 23.65M |
Valuation Ratios
The trailing PE ratio is 41.17 and the forward PE ratio is 35.00. Krystal Biotech's PEG ratio is 0.98.
| PE Ratio | 41.17 |
| Forward PE | 35.00 |
| PS Ratio | 19.11 |
| Forward PS | 15.31 |
| PB Ratio | 6.26 |
| P/TBV Ratio | 6.26 |
| P/FCF Ratio | 28.96 |
| P/OCF Ratio | 27.72 |
| PEG Ratio | 0.98 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 34.03, with an EV/FCF ratio of 25.14.
| EV / Earnings | 34.62 |
| EV / Sales | 16.58 |
| EV / EBITDA | 34.03 |
| EV / EBIT | 34.26 |
| EV / FCF | 25.14 |
Financial Position
The company has a current ratio of 7.89, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.89 |
| Quick Ratio | 7.35 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.03 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 17.50% and return on invested capital (ROIC) is 37.54%.
| Return on Equity (ROE) | 17.50% |
| Return on Assets (ROA) | 10.06% |
| Return on Invested Capital (ROIC) | 37.54% |
| Return on Capital Employed (ROCE) | 15.76% |
| Weighted Average Cost of Capital (WACC) | 7.81% |
| Revenue Per Employee | $1.59M |
| Profits Per Employee | $763,281 |
| Employee Count | 295 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 0.61 |
Taxes
In the past 12 months, Krystal Biotech has paid $33.63 million in taxes.
| Income Tax | 33.63M |
| Effective Tax Rate | 12.99% |
Stock Price Statistics
The stock price has increased by +53.12% in the last 52 weeks. The beta is 0.65, so Krystal Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | +53.12% |
| 50-Day Moving Average | 331.52 |
| 200-Day Moving Average | 309.12 |
| Relative Strength Index (RSI) | 41.24 |
| Average Volume (20 Days) | 337,777 |
Short Selling Information
The latest short interest is 2.94 million, so 9.91% of the outstanding shares have been sold short.
| Short Interest | 2.94M |
| Short Previous Month | 3.48M |
| Short % of Shares Out | 9.91% |
| Short % of Float | 12.41% |
| Short Ratio (days to cover) | 9.85 |
Income Statement
In the last 12 months, Krystal Biotech had revenue of $470.03 million and earned $225.17 million in profits. Earnings per share was $7.36.
| Revenue | 470.03M |
| Gross Profit | 443.12M |
| Operating Income | 227.52M |
| Pretax Income | 258.80M |
| Net Income | 225.17M |
| EBITDA | 229.03M |
| EBIT | 227.52M |
| Earnings Per Share (EPS) | $7.36 |
Balance Sheet
The company has $911.85 million in cash and $8.59 million in debt, with a net cash position of $1.19 billion or $40.01 per share.
| Cash & Cash Equivalents | 911.85M |
| Total Debt | 8.59M |
| Net Cash | 1.19B |
| Net Cash Per Share | $40.01 |
| Equity (Book Value) | 1.44B |
| Book Value Per Share | 48.45 |
| Working Capital | 979.62M |
Cash Flow
In the last 12 months, operating cash flow was $323.93 million and capital expenditures -$13.85 million, giving a free cash flow of $310.08 million.
| Operating Cash Flow | 323.93M |
| Capital Expenditures | -13.85M |
| Depreciation & Amortization | 1.51M |
| Net Borrowing | n/a |
| Free Cash Flow | 310.08M |
| FCF Per Share | $10.46 |
Margins
Gross margin is 94.28%, with operating and profit margins of 48.41% and 47.91%.
| Gross Margin | 94.28% |
| Operating Margin | 48.41% |
| Pretax Margin | 55.06% |
| Profit Margin | 47.91% |
| EBITDA Margin | 48.73% |
| EBIT Margin | 48.41% |
| FCF Margin | 65.97% |
Dividends & Yields
Krystal Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.44% |
| Shareholder Yield | -2.44% |
| Earnings Yield | 2.43% |
| FCF Yield | 3.45% |
Analyst Forecast
The average price target for Krystal Biotech is $388.22, which is 28.10% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $388.22 |
| Price Target Difference | 28.10% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 28.19% |
| EPS Growth Forecast (3Y) | 19.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Krystal Biotech has an Altman Z-Score of 34.47 and a Piotroski F-Score of 5.
| Altman Z-Score | 34.47 |
| Piotroski F-Score | 5 |